S&P 500 Futures
(0.67%) 4 354.50 points
Dow J Futures
(0.60%) 33 928 points
Nasdaq Futures
(0.93%) 15 004 points
Oil
(0.40%) $91.15
Gas
(-0.68%) $2.91
Gold
(-0.37%) $1 859.20
Silver
(-1.69%) $22.07
Platinum
(0.25%) 918.20
USD/EUR
(-0.09%) 0.945
USD/NOK
(-0.22%) 10.67
USD/GBP
(-0.09%) 0.819
USD/RUB
(1.84%) 98.25

Realtime updates for Ind-Swift Laboratories [INDSWFTLAB.NS]

Exchange: NSE Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic
Last Updated29 Sep 2023 @ 05:59

3.38% INR 90.35

Live Chart Being Loaded With Signals

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms...

Stats
Today's Volume 277 620
Average Volume 583 693
Market Cap 5.34B
P/E 11.39
ATR14 INR0.204 (0.23%)

Volume Correlation

Long: 0.94 (very strong)
Short: -0.86 (strong negative)
Signal:(47.276) Neutral

Ind-Swift Laboratories Correlation

10 Most Positive Correlations
PVP.NS0.827
ICICIPHARM.NS0.813
KIMS.NS0.811
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ind-Swift Laboratories Correlation - Currency/Commodity

The country flag 0.89
( strong )
The country flag 0.72
( moderate )
The country flag 0.82
( strong )
The country flag 0.30
( neutral )
The country flag -0.79
( moderate negative )
The country flag -0.89
( strong negative )

Ind-Swift Laboratories Financials

Annual 2023
Revenue: INR12.07B
Gross Profit: INR5.52B (45.70 %)
EPS: INR8.06
Q4 2023
Revenue: INR3.04B
Gross Profit: INR1.42B (46.62 %)
EPS: INR-4.24
Q3 2023
Revenue: INR3.13B
Gross Profit: INR1.30B (41.61 %)
EPS: INR4.65
Q2 2023
Revenue: INR3.10B
Gross Profit: INR1.44B (46.30 %)
EPS: INR4.29

Ind-Swift Laboratories Dividends

(Q3/04) 2004-09-23 (Q3/05) 2005-09-22 (Q3/06) 2006-09-22 (Q3/07) 2007-09-21 (Q3/08) 2008-09-18 (Q3/09) 2009-09-17 (Q3/10) 2010-09-16 (Q3/11) 2011-09-20
INR1.000
(Paid: 2004-10-10)
INR1.500
(Paid: 2005-10-11)
INR1.500
(Paid: 2006-11-01)
INR1.000
(Paid: 2007-11-01)
INR1.000
(Paid: 2008-11-01)
INR1.000
(Paid: 2009-10-24)
INR1.000
(Paid: 2010-10-22)
INR1.000
(Paid: 2011-10-26)

Ind-Swift Laboratories

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

Estimated
INDSWFTLAB.NS Next Dividend
(2024-06-27) INR1.069 Probabilty 100 %
Quarter Ratio
INDSWFTLAB.NS 0.10 0.02